|
GPhA Third-Party Shortages Plan Threatened by FTC’s Silence
The FTC may not issue the advisory opinion GPhA is waiting for before launching its third-party drug shortage program, possibly derailing the initiative.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives